Abstract #0149

Hyperpolarized [1-13C]/[5-13C] glutamate as a metabolic imaging marker of IDH1 mutant glioma response to temozolomide therapy

Elavarasan Subramani¹, Chloe Najac¹, Georgios Batsios¹, Marina Radoul¹, Pavithra Viswanath¹, Abigail Molloy¹, Donghyun Hong¹, Anne Marie Gillespie¹, Russell O. Pieper^2,3, Joseph Costello², and Sabrina M Ronen^1,3

¹Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, United States, ²Department of Neurological Surgery, Helen Diller Research Center, University of California San Francisco, San Francisco, CA, United States, ³Brain Tumor Research Center, University of California San Francisco, San Francisco, CA, United States

Temozolomide (TMZ) is most commonly used for the treatment of primary glioblastoma but is now being considered for the treatment of low-grade glioma that harbor mutations in the cytosolic isocitrate dehydrogenase 1 (IDH1) gene. Though the treatment of IDH1 mutant patients with TMZ improves survival, there is a need for complementary metabolic imaging approaches to help in assessing early response to therapy. Hyperpolarized ¹³C magnetic resonance spectroscopy-based metabolic profiling of mutant IDH1 cells treated with TMZ revealed that [1-¹³C]/[5-¹³C] glutamate production from [1-¹³C] α-ketoglutaric acid/[2-¹³C] pyruvate could serve as translatable biomarkers of response to therapy.

This abstract and the presentation materials are available to members only; a login is required.

Join Here